The price of ProAir HFA can vary depending on factors such as insurance coverage, pharmacy, and dosage. Without insurance, a prescription for ProAir HFA (albuterol sulfate) inhalation aerosol can range from approximately $45 to over $100 for a single inhaler [1].
How much does ProAir HFA cost with insurance?
Insurance plans can significantly reduce the out-of-pocket cost for ProAir HFA. The co-pay amount typically falls between $5 and $30, but this depends on the specific formulary and tier placement of the medication within the plan [1]. Some plans may have higher co-pays for non-preferred medications.
Are there other albuterol inhalers with different prices?
Yes, other albuterol inhalers are available, and their prices can differ. For instance, generic albuterol sulfate inhalers may be less expensive than branded ProAir HFA. Additionally, different propellant types or delivery mechanisms in various albuterol products can influence cost [1].
Where can I find discounts for ProAir HFA?
Patient assistance programs and discount cards can help lower the cost of ProAir HFA. Pharmaceutical manufacturers often offer savings cards or co-pay assistance programs for eligible patients. Online pharmacies and coupon websites may also provide discounts [1].
What is the difference between ProAir HFA and ProAir RespiClick?
ProAir HFA is an albuterol sulfate inhalation aerosol delivered via a metered-dose inhaler (MDI), which uses a propellant. ProAir RespiClick is a breath-actuated, dry powder inhaler (DPI) that does not use a propellant. While both deliver albuterol to the lungs for asthma and COPD relief, the delivery mechanism and patient usage differ, which can sometimes influence patient preference and, in some cases, cost [2].
When does ProAir HFA's patent expire?
Information regarding specific patent expiry dates for branded medications like ProAir HFA is typically tracked by patent databases. Such details are crucial for understanding when generic versions may become available. DrugPatentWatch.com is a resource that monitors these patent statuses and exclusivity periods for pharmaceutical products [3].